Vaccination

Bavarian Nordic’s Chikungunya Vaccine Candidate Granted Accelerated Assessment by European Medicines Agency

Retrieved on: 
Friday, February 23, 2024
Marketing, EMA, Marketing Authorisation Application, Committee, MAA, Food, BLA, Nature, Vaccination, CHMP, European Medicines Agency, Public, Chikungunya, OMX, Ageing, CHIKV, Vaccine

Bavarian Nordic is on track to submit its Marketing Authorisation Application for CHIKV VLP to EMA during H1 2024.

Key Points: 
  • Bavarian Nordic is on track to submit its Marketing Authorisation Application for CHIKV VLP to EMA during H1 2024.
  • COPENHAGEN, Denmark, February 23, 2024 – Bavarian Nordic A/S (OMX: BAVA) (“the Company”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted accelerated assessment for the upcoming Marketing Authorisation Application (MAA) for CHIKV VLP, the Company’s investigational chikungunya vaccine.
  • Bavarian Nordic is on track and plans to submit its MAA for CHIKV VLP to the EMA during H1 2024.
  • “We are pleased to receive the accelerated assessment in recognition of our chikungunya vaccine candidate and our efforts to bring this novel product to the market.

Prevent Cancer Foundation awards $1 million in new research grants

Retrieved on: 
Wednesday, February 21, 2024
Head, Breast cancer, Neck, Cancer, Woman, Survivor, Diet, Reproductive medicine, Assistant, Melanoma, Blood, Uterus, Biostatistics, Skin, Immunodeficiency, Database, Communication, Risk, FACP, Breast, University, Stomach, Vaccination, MD Anderson Cancer Center, Member of Congress, Genetic, Dicarboxylic acid, Drinking, Ovarian cancer, Genetics, Squamous-cell carcinoma, Death, Associate, Genetic testing, Black, Huntsman Cancer Institute, SCCS, Disease, HPV, Knowledge, Health literacy, Mortality, New York University, Research, University of North Carolina, Partnership, Birth control

Alexandria, Va., Feb. 21, 2024 (GLOBE NEWSWIRE) -- The Prevent Cancer Foundation® is pleased to announce new funding for ten scientists who are researching cancer prevention and early detection.

Key Points: 
  • Alexandria, Va., Feb. 21, 2024 (GLOBE NEWSWIRE) -- The Prevent Cancer Foundation® is pleased to announce new funding for ten scientists who are researching cancer prevention and early detection.
  • Read on for more on the 2024 research grantees or access more detailed information on their projects in the researcher database.
  • Having a family history of cancer can affect the age at which cancer screening begins and genetic testing recommendations.
  • To view all past funded research grant and fellowship projects driving these key advancements in cancer prevention and early detection, explore the Prevent Cancer Foundation’s Award Database.

Global-E Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Wednesday, February 21, 2024
Acquisition, Growth, Calendar, Adjustment, Vaccination, GAAP, COVID-19, Webcast, GMV, Tax, Security (finance), Depreciation, Bank

See “Non-GAAP Financial Measures” for additional information regarding this metric, including the reconciliations to Operating Profit (Loss), its most directly comparable GAAP financial measure.

Key Points: 
  • See “Non-GAAP Financial Measures” for additional information regarding this metric, including the reconciliations to Operating Profit (Loss), its most directly comparable GAAP financial measure.
  • Such information may have a significant, and potentially unpredictable impact on the Company’s future financial results.
  • Global-e’s definition of Non-GAAP measures may differ from the definition used by other companies and therefore comparability may be limited.
  • These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTech SE of Class Action Lawsuit and Upcoming Deadlines – BNTX

Retrieved on: 
Tuesday, February 20, 2024
Pfizer–BioNTech COVID-19 vaccine, Pfizer, Third Bridge, ADS, Pomerantz, Cancer, Court, Biotechnology, Person, BioNTech, Omicron, Prior, News, Food, Complaint, District court, Risk, Ext, Vaccination, EUR, COVID-19, BNTX, COVID, LLP, Infection, Action Replay, Cost, Research, Pharmaceutical industry

NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX).

Key Points: 
  • NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX).
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise

Retrieved on: 
Thursday, March 7, 2024
Infectious Diseases, General Health, Health, Other Health, Inflation, Senior, Immunization, GSK, Education, Physician, Hope, Entrepreneurship, Vaccine, Vaccination, American Lung Association, Patient, Request, IRA, Health equity, Infection, Medicaid, GSK plc, Pharmaceutical industry

GSK plc (LSE/NYSE: GSK) today announced additional funding and new data and resources under the COiMMUNITY Initiative to help achieve higher adult vaccination rates and health equity in the US and address ongoing barriers to adult immunization.

Key Points: 
  • GSK plc (LSE/NYSE: GSK) today announced additional funding and new data and resources under the COiMMUNITY Initiative to help achieve higher adult vaccination rates and health equity in the US and address ongoing barriers to adult immunization.
  • The COiMMUNITY Initiative complements recent industry and regulatory efforts to expand and improve adult vaccine availability, coverage and access.
  • GSK is equipping healthcare providers and their patients with simple tools to spur action and follow through on vaccination.
  • GSK will also continue to share new resources, tools and best practices in adult vaccine confidence and delivery via interactive webinars.

Rite Aid and Bartell Drugs Announce Additional Dose of Updated COVID-19 Vaccine Available for Customers Ages 65 and Older

Retrieved on: 
Tuesday, March 5, 2024
Retail, Health, Convenience Store, COVID-19, Specialty, General Health, Pharmaceutical, OTC, Rite Aid, Vaccination, ACIP, Aid, Senior, Pharmacist, CDC, Pacific Northwest, Vaccine

Rite Aid (OTC:RADCQ) recently announced that appointments are now available for eligible customers ages 65 and older seeking an additional dose of the updated COVID-19 (2023-2024) vaccines at its locations, including Bartell Drugs locations in the Pacific Northwest.

Key Points: 
  • Rite Aid (OTC:RADCQ) recently announced that appointments are now available for eligible customers ages 65 and older seeking an additional dose of the updated COVID-19 (2023-2024) vaccines at its locations, including Bartell Drugs locations in the Pacific Northwest.
  • “Rite Aid wants to ensure our customers safeguard their health, especially those in vulnerable populations, including our customers ages 65 and older.”
    The updated COVID-19 vaccine provides enhanced protection against currently circulating variants of COVID-19.
  • According to the new recommendation, all customers ages 65 and older who previously received the COVID-19 vaccine (2023-2024) should receive an additional dose four months after receipt of the prior dose.
  • Rite Aid pharmacists are trained to immunize customers ages three and older based on the CDC's vaccine guidelines and state regulations.

DocGo Announces Record Fourth Quarter and Full-Year 2023 Results

Retrieved on: 
Wednesday, February 28, 2024
Health, Telemedicine, Virtual Medicine, Health Technology, Practice Management, Managed Care, General Health, Conference call, Hospital, RPM, Share repurchase, Cardiology, Growth, Government, Risk, Conference, Vaccination, Treasurer, GAAP, Remote patient monitoring, Webcast, Patient, Uncertainty, L.A. Care Health Plan, VCM, Insurance, Transport, Partnership, Video game

Gross margin for the fourth quarter of 2023 was 33.5%, compared to 39.0% in the fourth quarter of 2022.

Key Points: 
  • Gross margin for the fourth quarter of 2023 was 33.5%, compared to 39.0% in the fourth quarter of 2022.
  • Adjusted EBITDA2 was $22.6 million for the fourth quarter of 2023 compared to $6.8 million for the fourth quarter of 2022, an increase of 232%.
  • Mobile Health Services revenues in the fourth quarter of 2023 were $150.4 million, compared to $71.8 million for the fourth quarter of 2022, an increase of 110%.
  • Transportation Services revenues in the fourth quarter of 2023 were $48.8 million compared to $37.0 million for the fourth quarter of 2022, an increase of 32%.

New Study Shows Increase in Pharmacy Reimbursement Leads to Higher Adult Medicaid Flu Vaccination Rates

Retrieved on: 
Tuesday, February 27, 2024
Practice Management, Professional Services, Managed Care, Other Health, Health, Seniors, Pharmaceutical, Health Insurance, Family, Insurance, Consumer, Pharmacy, Research, Immunization, Doctor of Pharmacy, Pharmacist, Vaccination, Medicare, Patient, Policy, Pharmaceutical industry

The Global Healthy Living Foundation (GHLF) co-released a groundbreaking report that found a direct link between pharmacy reimbursement and flu vaccination rates among Medicaid-covered adults.

Key Points: 
  • The Global Healthy Living Foundation (GHLF) co-released a groundbreaking report that found a direct link between pharmacy reimbursement and flu vaccination rates among Medicaid-covered adults.
  • According to co-researcher Vibhu Tewary, Project Director, IQVIA Institute for Human Data Science, “a $13 increase in pharmacy reimbursement for adult flu vaccination was associated with a nearly 6 percent point surge in the state vaccination rate for Medicaid fee-for-service covered adults.”
    To put it in perspective, a mere $1 increment in Medicaid fee-for-service pharmacy reimbursement for adult flu vaccines translates to a half-percentage-point boost in vaccination rates.
  • Adults under Medicaid coverage often face significant disparities in vaccination rates compared to individuals with commercial insurance or Medicare coverage.
  • Research consistently shows that broadening pharmacy vaccination authority will increase immunization rates, reduce healthcare costs, and save lives.

Akston Biosciences' AKS-452 Vaccine Study Published in Nature, Showcasing Ambifect® Platform's Versatility

Retrieved on: 
Monday, February 26, 2024
Health, Infectious Diseases, Clinical Trials, Research, Science, Biotechnology, Veterinary, MERS, Dengue fever, Atopic dermatitis, Kinetics, RBD, Vaccination, Immunoglobulin G, Chronic pain, Nerve growth factor, Dementia, Protein, Infection, CGMP, Notifiable disease, Immune system, Vaccine

This Netherlands study showed the ability of a 90 ug subcutaneous dose to safely boost the immune response of individuals previously primed with a registered mRNA- or adenovirus-based SARS-CoV-2 vaccine.

Key Points: 
  • This Netherlands study showed the ability of a 90 ug subcutaneous dose to safely boost the immune response of individuals previously primed with a registered mRNA- or adenovirus-based SARS-CoV-2 vaccine.
  • Fc-fusion protein vaccines derived from Akston’s platform provide a unique set of benefits, including inherent stability at ambient temperatures and low-cost, high-volume manufacture.
  • AKS-452 is a subunit vaccine consisting of an Fc fusion of the SARS-CoV-2 spike protein receptor binding domain (SP/RBD).
  • “Akston has also made significant strides in demonstrating the Ambifect® platform's potential beyond infectious disease vaccination,” said Todd Zion, Ph.D., President & CEO of Akston Biosciences.

Roha Medical Campus, a World-Class Hospital in Ethiopia, Gets $42 Million First Injection

Retrieved on: 
Thursday, February 22, 2024
Hospitals, Finance, Banking, Professional Services, Public Policy, Government, Healthcare Reform, Transportation, General Health, Health, Travel, Stroke, Diabetes, Cancer, Hospital, Economic development, Neurosurgery, Spine, Research, Flood, Physician, Respiratory failure, Quality of life, Death, African Union, Medical tourism, Urbanization, Emergency, Elective surgery, Carbon, RMC, Vaccination, Health care, Tree, International airport, Patient, Teaching, Nuclear medicine, African, Map, Tuberculosis, Infection, Mortality, HIV, Notifiable disease, Environment

The equity funding represents the first tranche of a US$130 million investment to build phase 1 of Roha Medical Campus, a 350-bed world-class hospital.

Key Points: 
  • The equity funding represents the first tranche of a US$130 million investment to build phase 1 of Roha Medical Campus, a 350-bed world-class hospital.
  • Designed to be Ethiopia’s first JCI-accredited1 hospital, Roha Medical Campus will alleviate an acute shortage of advanced medical facilities and healthcare services for Africa’s second largest nation and patients in the region.
  • “Ethiopian Airlines’ global connectivity strengthens the case for medical tourism and ensures strong US dollar revenue for the hospital.
  • Roha Medical Campus will reduce costs and increase accessibility relative to other local hospitals and comparable international medical tourism packages.